TEM Tempus AI Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
14:06
Jul 10
Jul 10
The author dismisses the ARKK portfolio as an avoid list without taking a directional position on any individual ticker.
14:37
Jul 07
Jul 07
The author expresses amazement at buying TEM in the 40s after its run to $100+, indicating a confident long position from lower levels.
15:28
Jul 06
Jul 06
Author lists higher-risk tickers in a reply to a thematic research post, but the reply lacks explicit position language or a forward call, so each ticker is indexed as watch.
LOW
18:17
Jul 01
Jul 01
Author is currently holding TEM following a breakout, viewing the price action as a leading signal for broader strength in the bio-health and genome sector; ongoing position with sector momentum thesis.
MED
16:41
Jul 01
Jul 01
Multiple FDA approvals and clearances for AI-driven cardiovascular and tumor detection support continued upside to $75.
MED
12:15
Jul 01
Jul 01
Author discloses an existing long position in Tempus AI ($TEM), responding to a direct question about the stock with confirmation of current ownership.
MED
18:12
Jun 29
Jun 29
Buy TEM on momentum breakout in AI healthcare, citing multiple FDA approvals and sector tailwinds.
MED
04:44
Jun 27
Jun 27
Author suggests scaling into TEM on red days but does not state a current position or explicit forward call.
16:11
Jun 25
Jun 25
Buy TEM on FDA-cleared AI tools for cardiovascular and oncology, supported by a technical breakout in a growing health‑tech sector.
MED
14:47
Jun 25
Jun 25
$TEM is breaking out according to the author, but no position or forward call is stated, so it is indexed as a watch.
LOW
17:25
Jun 20
Jun 20
Author notes strong fundamentals on both TEM and ZETA but does not state a personal position or forward directional call.
LOW
23:57
Jun 15
Jun 15
Author describes Tempus AI's business profile and leadership in healthcare AI, but does not state a personal directional view or position.
LOW
17:06
Jun 15
Jun 15
Describes TEM's FDA approvals and AI role in early AFib detection; presents a positive sector view but no personal directional commitment.
MED
16:07
Jun 08
Jun 08
Author discloses a newly added long position in TEM; no specific catalyst stated beyond portfolio addition.
MED
15:32
Jun 08
Jun 08
Author gives a vague, hype-driven teaser about $TEM with no catalyst or directional commitment.
LOW
13:21
Jun 05
Jun 05
Author confirms a new long position in Tempus AI (TEM), added to long-term portfolio; no specific catalyst stated beyond deliberate portfolio inclusion.
MED
18:54
Jun 04
Jun 04
Buy TEM near-term on large options flow — a $551K call buyer was flagged in the parent thread, and the author expects a double-digit percentage move the following session based on that positioning signal.
MED
16:19
Jun 04
Jun 04
Buy TEM as unusual call options activity signals near-term upside toward the $60 price target, with options flow providing a concrete directional catalyst.
MED
16:10
Jun 04
Jun 04
Buy TEM as a play on an anticipated rotation into biotech/healthcare; author has entered a position expecting the sector to catch up to broader market performance.
MED
15:33
Jun 04
Jun 04
WATCH TEM as mild bullish recognition/commentary; no position, buy, or concrete thesis disclosed.
WATCH TEM as mild bullish recognition/commentary; author says the stock is finally getting recognition but does not disclose a position, buy, or concrete thesis in this tweet.
16:05
Jun 01
Jun 01
The author's brief reply "Time for tem" is too vague to confirm a directional position, so TEM is indexed as a watch.
LOW
12:39
May 29
May 29
Buy TEM; FDA approval for xT CDx genomic test unlocks unified ADLT pricing across the full solid tumor DNA portfolio, with management guiding to a ~$200 ASP benefit beginning 2027 — a concrete revenue catalyst the author explicitly wishes they had more exposure to.
MED
00:56
May 27
May 27
Tempus AI for AI healthcare
Tempus AI is a healthcare AI software company with strong AI integration. As the market shifts toward AI-embedded healthcare, Tempus offers specific exposure to this theme, with potential for growth in diagnostics and precision medicine.
MED
20:02
May 05
May 05
Tempus AI reported Q1 revenue in line with estimates and raised 2026 guidance, but the tweet is a factual earnings summary without a forward-looking opinion.
HIGH
10:22
Apr 19
Apr 19
Likes Tempus AI; accommodating FDA + AI-augmented biotech R&D thesis, accumulate equity pullbacks.
MED
17:38
Apr 17
Apr 17
Names Tempus AI as a current pick (AI-biotech / FDA thesis restated from prior posts).
LOW
About TEM Analyst Coverage
Buzzberg tracks TEM (Tempus AI) across 7 sources. 14 bullish vs 0 bearish calls from 8 analysts. Sentiment: predominantly bullish (54%). 26 total trade ideas tracked. Past 7 days: 3 watch. Latest voices: tacticzh, caesarcapitalz, incomesharks.